破裂瘤泡以改善CAR T细胞疗法
Sergio Ortiz-Espinosa1, Shivani Srivastava1
1Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Cancer research
|August 15, 2023
概括
瘤衍生的细胞外囊泡 (EVs) 通过输送向抗原和PD-L1.1,抑制CAR T细胞对固体瘤的活性. 抑制EV分泌增强了CAR T细胞功能和抗瘤功效,提供了一种新的治疗策略.
科学领域:
- 免疫治疗是一种免疫疗法.
- 细胞外囊泡 细胞外囊泡
- 固体瘤瘤学 固体瘤瘤学
背景情况:
- 化学抗原受体 (CAR) T细胞疗法在B细胞癌症中取得了成功,但在固体瘤中有效性有限.
- 在固体瘤中限制CAR-T细胞活性的机制仍然不完全理解.
研究的目的:
- 研究瘤衍生小细胞外囊 (sEVs) 在抑制固体瘤中CAR T细胞活性中的作用.
- 探索针对sEV分泌的策略,以增强CAR T细胞治疗.
主要方法:
- 在瘤衍生的sEV中分析CAR向抗原和PD-L1表达.
- 在体内研究评估CAR T细胞与sEV相互作用以及PD-L1阻塞的影响.
- 对sEV分泌的遗传和药理抑制对CAR T细胞疗效的评估.
主要成果:
- 发现瘤衍生的sEVs含有CAR基抗原 (例如,美索特林) 并与CAR T细胞相互作用.
- 在sEVs上PD-L1表达增加了CAR T细胞输液后,导致PD-L1依赖的CAR T细胞抑制.
- 抑制sEV分泌在体内显著改善了CAR T细胞的积累,功能和抗瘤活性.
结论:
- 来自瘤的sEVs在固体瘤中代表了CAR T细胞抑制的重要机制.
- 向sEV分泌是一种有前途的治疗方法,可以克服固体瘤中CAR T细胞的抗性.
相关概念视频
Tumor Immunotherapy
557
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
557
The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Cytotoxic T Cells-mediated Immune Response
971
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
971


